Form 4: Tarsus Director Converts RSUs to Common Stock

Tarsus Pharmaceuticals Director Katherine Goodrich converted 2,233 Restricted Stock Units into common stock on December 15, 2025.

Summary

• Katherine Goodrich, a Director of Tarsus Pharmaceuticals, Inc. (TARS), reported a transaction on December 15, 2025.
• She acquired 2,233 shares of Tarsus Pharmaceuticals Common Stock.
• This acquisition resulted from the settlement of 2,233 vested Restricted Stock Units (RSUs).
• Following this transaction, she beneficially owns 2,233 shares of Common Stock directly.
• She also beneficially owns 4,467 Restricted Stock Units (RSUs) directly.
• The remaining 4,467 RSUs will vest in three equal installments on December 15, 2025, 2026, and 2027, contingent on her continuous service.

Sentiment

Score: 7

Explanation: The filing reports a routine, positive event where a director converts vested equity compensation into common stock, increasing their direct ownership. This is generally viewed favorably as it aligns insider interests with shareholders, though it's a standard compensation event rather than a significant strategic announcement.

Positives

• Director Katherine Goodrich increased her direct ownership of common stock by 2,233 shares, aligning her interests with shareholders.
• The conversion of RSUs indicates a vesting event, suggesting continued service and commitment from a key director.

Future Outlook

The filing indicates future vesting events for Katherine Goodrich's remaining 4,467 Restricted Stock Units on December 15, 2026, and December 15, 2027, contingent on her continuous service to the company.

Industry Context

This Form 4 reports a routine insider transaction related to equity compensation. Such transactions are common in the pharmaceutical industry, where executive and director compensation often includes stock-based awards to align interests with long-term company performance. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting the conversion of Restricted Stock Units (RSUs) into common stock for a director.
• This type of equity compensation and subsequent conversion is a common practice across publicly traded companies, including those in the biotechnology and pharmaceutical sectors like Tarsus Pharmaceuticals.
• There are no specific comparable companies, projects, or results mentioned in this filing to assess against industry benchmarks beyond the general practice of RSU vesting.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be seen as a positive signal of alignment with shareholder interests.

Next Steps

• Future vesting of 4,467 Restricted Stock Units in two equal installments on December 15, 2026, and December 15, 2027, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details a routine conversion of Restricted Stock Units (RSUs) into common stock by a director. While it shows continued insider ownership and alignment, it does not present new information that would fundamentally alter the investment thesis for Tarsus Pharmaceuticals. It's a standard compensation event and does not warrant a change in investment recommendation based solely on this filing.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Director Stock Ownership, Equity Compensation